Tirzepatide and the 10‐year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three‐year SURMOUNT ‐1 trial
Authors' conclusion
Tirzepatide treatment was associated with a reduction in the 10-year predicted risk of both cardiovascular outcomes and T2D in people with obesity and prediabetes.
Study context
- Population
- Adults with obesity and prediabetes at baseline, 3-year SURMOUNT-1 trial participants
- Comparison
- Once-weekly tirzepatide vs placebo
- Primary endpoint
- Change in 10-year predicted risk of cardiovascular disease (CVD) (ASCVD, HF, total CVD) and T2D from validated risk engines
- Follow-up
- Baseline to week 176
Methodological detailsvalidated risk engines, mixed model of repeated measures
- Validated risk engines
- Mixed model of repeated measures
Primary result
As reported in the abstract
Mean % change in predicted 10-year ASCVD risk score (ACC/AHA equations)
Tirzepatide 5 mg
−4.6%
mean
Tirzepatide 10 mg
−7.5%
mean
Tirzepatide 15 mg
−9.2%
mean
Placebo
57.9%
mean
P < 0.0001 for all
Further findings
Mean
| Outcome | Tirzepatide 5 mg | Tirzepatide 10 mg | Tirzepatide 15 mg | Placebo | P value |
|---|---|---|---|---|---|
| Mean % change in predicted 10-year ASCVD risk score (PREVENT equations) · baseline to week 176Tirzepatide (each dose) vs Placebo · greater reduction with tirzepatide | −3.7% | −6.3% | −8.8% | 40.5% | P < 0.0001 for all |
| Mean absolute change in T2D risk score (CMDS) · baseline to week 176Tirzepatide (each dose) vs Placebo · greater reduction with tirzepatide | −17.0% | −19.6% | −19.5% | −4.3% | P < 0.0001 |
Original publication
Tirzepatide and the 10‐year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three‐year SURMOUNT ‐1 trial. Diabetes Obes Metab. Published 29 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →